nintedanib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
angiogenesis inhibitors	4903	656247-17-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: BIBF1120 nibtedanib nintedanib nintedanib esylate intedanib BIBF 1120 ofev nintedanib ethanesulfonate vargatef	Molecular weight: 539.64 Formula: C31H33N5O4 CLOGP: 3.08 LIPINSKI: 1 HAC: 9 HDO: 2 TPSA: 94.22 ALOGS: -4.24 ROTB: 8 Status: ONP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

BIBF1120
nibtedanib
nintedanib
nintedanib esylate
intedanib
BIBF 1120
ofev
nintedanib ethanesulfonate
vargatef

Molecular weight: 539.64
Formula: C31H33N5O4
CLOGP: 3.08
LIPINSKI: 1
HAC: 9
HDO: 2
TPSA: 94.22
ALOGS: -4.24
ROTB: 8

Status: ONP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.38	g	O

ADMET properties:

Property	Value	Reference
Vd (Volume of distribution)	15 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	19.90 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.02 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	9.50 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company
July 3, 2015	PMDA	Boehringer Ingelheim
Oct. 15, 2014	FDA	BOEHRINGER INGELHEIM
Nov. 20, 2014	EMA	Boehringer Ingelheim International GmbH

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Diarrhoea	976.93	22.91	934	11917	714432	62761739
Nausea	318.93	22.91	594	12257	853877	62622294
Decreased appetite	266.39	22.91	289	12562	250763	63225408
Malignant neoplasm progression	242.80	22.91	170	12681	81951	63394220
Vomiting	242.07	22.91	416	12435	559201	62916970
Death	160.73	22.91	278	12573	374103	63102068
Weight decreased	123.09	22.91	209	12642	276589	63199582
Drug ineffective	102.72	22.91	42	12809	1044723	62431448
Dyspnoea	97.69	22.91	324	12527	660989	62815182
Drug-induced liver injury	78.30	22.91	65	12786	40157	63436014
Cough	68.91	22.91	170	12681	292573	63183598
Flatulence	67.37	22.91	56	12795	34646	63441525
Gamma-glutamyltransferase increased	62.12	22.91	53	12798	33978	63442193
Mucosal infection	61.95	22.91	13	12838	189	63475982
Idiopathic pulmonary fibrosis	61.31	22.91	19	12832	1373	63474798
Constipation	57.57	22.91	135	12716	224808	63251363
Liver disorder	55.20	22.91	61	12790	53626	63422545
Oxygen saturation decreased	50.38	22.91	75	12776	88510	63387661
Dyspnoea exertional	47.84	22.91	60	12791	60242	63415929
Pneumothorax	46.40	22.91	33	12818	16228	63459943
Hepatotoxicity	45.00	22.91	46	12805	36995	63439176
Liver function test increased	44.01	22.91	43	12808	32768	63443403
Drug hypersensitivity	40.64	22.91	7	12844	310680	63165491
Epistaxis	40.52	22.91	61	12790	72664	63403507
Pulmonary hypertension	39.57	22.91	43	12808	37080	63439091
Infusion related reaction	38.36	22.91	3	12848	245518	63230653
Productive cough	36.62	22.91	54	12797	63154	63413017
Pulmonary embolism	36.55	22.91	76	12775	116608	63359563
Arthropathy	36.31	22.91	3	12848	234789	63241382
Hepatic function abnormal	36.11	22.91	41	12810	37101	63439070
Aspartate aminotransferase increased	35.84	22.91	65	12786	90212	63385959
Faeces soft	35.42	22.91	19	12832	5673	63470498
Abnormal loss of weight	35.14	22.91	19	12832	5763	63470408
Respiratory failure	35.06	22.91	69	12782	101789	63374382
Alanine aminotransferase increased	34.16	22.91	69	12782	103701	63372470
Joint swelling	33.92	22.91	12	12839	327654	63148517
Abdominal pain upper	33.69	22.91	105	12746	206339	63269832
Product use issue	33.60	22.91	3	12848	220517	63255654
Interstitial lung disease	33.17	22.91	51	12800	61857	63414314
Pain	32.59	22.91	63	12788	740565	62735606
White blood cell count decreased	29.73	22.91	78	12773	139026	63337145
Swelling	28.64	22.91	10	12841	275368	63200803
Arthralgia	28.17	22.91	45	12806	569665	62906506
Intestinal haemorrhage	27.23	22.91	14	12837	3833	63472338
Metastases to central nervous system	27.21	22.91	22	12829	13083	63463088
Neutrophil count decreased	26.82	22.91	44	12807	56362	63419809
Rheumatoid arthritis	26.77	22.91	9	12842	253810	63222361
Hypersensitivity	26.61	22.91	13	12838	292672	63183499
Disease progression	26.40	22.91	69	12782	122689	63353482
Transaminases increased	26.13	22.91	32	12819	31335	63444836
Large intestine perforation	26.03	22.91	18	12833	8464	63467707
Stomatitis	25.87	22.91	74	12777	138651	63337520
Pneumomediastinum	25.68	22.91	10	12841	1426	63474745
Pneumonia	24.42	22.91	167	12684	456600	63019571
Total lung capacity abnormal	23.81	22.91	5	12846	73	63476098
Dairy intolerance	23.56	22.91	5	12846	77	63476094
Haemoptysis	23.44	22.91	29	12822	28697	63447474
Fatigue	23.36	22.91	278	12573	887750	62588421

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Diarrhoea	1491.64	19.90	1333	15729	388579	34551290
Malignant neoplasm progression	440.44	19.90	355	16707	87691	34852178
Decreased appetite	351.43	19.90	418	16644	165974	34773895
Death	259.82	19.90	586	16476	397463	34542406
Weight decreased	246.40	19.90	362	16700	175939	34763930
Pneumothorax	188.69	19.90	117	16945	18975	34920894
Dyspnoea	176.90	19.90	490	16572	376292	34563577
Lung transplant	151.21	19.90	51	17011	1973	34937896
Nausea	137.94	19.90	420	16642	339488	34600381
Cough	118.82	19.90	240	16822	149900	34789969
Faeces soft	87.80	19.90	40	17022	3468	34936401
Abnormal loss of weight	84.96	19.90	41	17021	4049	34935820
Productive cough	80.93	19.90	96	16966	37717	34902152
Respiratory failure	73.50	19.90	163	16899	108409	34831460
Liver disorder	70.98	19.90	84	16978	32913	34906956
Idiopathic pulmonary fibrosis	69.12	19.90	34	17028	3500	34936369
Drug-induced liver injury	64.68	19.90	75	16987	28757	34911112
Drug ineffective	61.55	19.90	80	16982	456671	34483198
Abdominal pain upper	58.44	19.90	116	16946	71374	34868495
Pulmonary fibrosis	53.73	19.90	55	17007	18341	34921528
Pulmonary embolism	53.27	19.90	128	16934	89618	34850251
Pulmonary function test decreased	50.40	19.90	31	17031	4944	34934925
Chronic respiratory failure	47.83	19.90	20	17042	1409	34938460
Lung neoplasm malignant	47.20	19.90	50	17012	17345	34922524
Hepatic enzyme increased	46.85	19.90	75	16987	39005	34900864
Constipation	46.73	19.90	160	16902	136822	34803047
Pulmonary hypertension	46.20	19.90	54	17008	20870	34918999
Oxygen saturation decreased	45.99	19.90	89	16973	53729	34886140
Drug interaction	45.49	19.90	27	17035	225919	34713950
Toxicity to various agents	44.66	19.90	21	17041	200341	34739528
Abdominal discomfort	44.04	19.90	93	16969	59742	34880127
Gastrointestinal disorder	41.86	19.90	66	16996	33882	34905987
Vomiting	41.84	19.90	234	16828	247387	34692482
Flatulence	40.75	19.90	51	17011	21147	34918722
Forced vital capacity decreased	40.57	19.90	15	17047	761	34939108
Off label use	37.94	19.90	94	16968	419430	34520439
Pneumonia	37.91	19.90	304	16758	362323	34577546
Acute kidney injury	37.39	19.90	57	17005	304931	34634938
Fatigue	36.20	19.90	306	16756	370347	34569522
Pneumonia bacterial	35.58	19.90	36	17026	11836	34928033
Dyspnoea exertional	35.06	19.90	70	16992	43209	34896660
Hepatic function abnormal	35.04	19.90	71	16991	44292	34895577
Stomatitis	34.73	19.90	69	16993	42445	34897424
Completed suicide	34.04	19.90	4	17058	98164	34841705
Pneumomediastinum	32.59	19.90	18	17044	2349	34937520
General physical health deterioration	32.27	19.90	136	16926	128133	34811736
Dysgeusia	31.95	19.90	51	17011	26446	34913423
Oxygen consumption increased	29.29	19.90	14	17048	1352	34938517
Epistaxis	29.22	19.90	78	16984	58173	34881696
Metastases to central nervous system	28.55	19.90	27	17035	8178	34931691
Haemoglobin decreased	27.91	19.90	12	17050	120760	34819109
Overdose	26.47	19.90	6	17056	91053	34848816
Drug hypersensitivity	26.20	19.90	4	17058	80525	34859344
Colitis ischaemic	25.82	19.90	23	17039	6452	34933417
Hypotension	25.64	19.90	43	17019	221606	34718263
Confusional state	25.28	19.90	20	17042	144140	34795729
Haemoptysis	25.27	19.90	54	17008	34952	34904917
Product use in unapproved indication	25.11	19.90	13	17049	117486	34822383
Product dose omission issue	24.49	19.90	14	17048	119697	34820172
Interstitial lung disease	23.76	19.90	78	16984	65204	34874665
Coating in mouth	23.48	19.90	6	17056	85	34939784
Splenic vein thrombosis	23.44	19.90	9	17053	507	34939362
Liver function test increased	23.27	19.90	32	17030	14533	34925336
Polyneuropathy	22.71	19.90	32	17030	14864	34925005
Mesenteric vein thrombosis	22.25	19.90	10	17052	839	34939030
Post procedural pneumonia	21.69	19.90	6	17056	117	34939752
Product use issue	20.89	19.90	3	17059	63213	34876656
Bradycardia	19.95	19.90	6	17056	75412	34864457

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Diarrhoea	2062.82	18.04	1940	24753	878549	78839146
Malignant neoplasm progression	801.23	18.04	522	26171	135468	79582227
Decreased appetite	564.96	18.04	631	26062	341787	79375908
Death	505.04	18.04	770	25923	565744	79151951
Nausea	336.51	18.04	881	25812	956315	78761380
Weight decreased	314.04	18.04	482	26211	354716	79362979
Pneumothorax	241.36	18.04	138	26555	28185	79689510
Dyspnoea	211.83	18.04	697	25996	856328	78861367
Vomiting	194.23	18.04	574	26119	665254	79052441
Drug-induced liver injury	136.96	18.04	138	26555	65979	79651716
Drug ineffective	133.23	18.04	101	26592	1080812	78636883
Cough	124.89	18.04	335	26358	366454	79351241
Liver disorder	123.03	18.04	136	26557	72281	79645414
Faeces soft	117.89	18.04	57	26636	8266	79709429
Lung transplant	115.64	18.04	47	26646	4514	79713181
Idiopathic pulmonary fibrosis	105.25	18.04	43	26650	4185	79713510
Constipation	103.89	18.04	266	26427	282784	79434911
Flatulence	101.21	18.04	96	26597	42628	79675067
Respiratory failure	99.87	18.04	200	26493	180711	79536984
Pulmonary embolism	93.82	18.04	189	26504	171465	79546230
Toxicity to various agents	88.42	18.04	17	26676	421523	79296172
Abnormal loss of weight	79.98	18.04	44	26649	8332	79709363
Hepatic function abnormal	78.44	18.04	109	26584	72998	79644697
Drug hypersensitivity	72.01	18.04	8	26685	298908	79418787
Productive cough	69.55	18.04	114	26579	88217	79629478
Pulmonary hypertension	69.33	18.04	83	26610	47997	79669698
Dyspnoea exertional	66.70	18.04	111	26582	86962	79630733
Abdominal pain upper	65.77	18.04	194	26499	223625	79494070
Oxygen saturation decreased	65.65	18.04	138	26555	128909	79588786
Infusion related reaction	64.43	18.04	3	26690	230234	79487461
Gamma-glutamyltransferase increased	63.91	18.04	85	26608	54595	79663100
Pneumonia	61.96	18.04	405	26288	659841	79057854
Epistaxis	61.14	18.04	123	26570	111392	79606303
Pneumomediastinum	57.69	18.04	27	26666	3640	79714055
Mucosal infection	56.54	18.04	16	26677	503	79717192
Stomatitis	55.90	18.04	140	26553	146617	79571078
Forced vital capacity decreased	54.84	18.04	21	26672	1722	79715973
Off label use	53.47	18.04	143	26550	907072	78810623
Interstitial lung disease	53.34	18.04	117	26576	112483	79605212
Haemoptysis	52.02	18.04	78	26615	55921	79661774
Joint swelling	51.97	18.04	16	26677	288630	79429065
Metastases to central nervous system	51.08	18.04	43	26650	16332	79701363
Lung neoplasm malignant	50.31	18.04	54	26639	27738	79689957
Fatigue	49.92	18.04	502	26191	929225	78788470
Chronic respiratory failure	49.87	18.04	23	26670	2999	79714696
Liver function test increased	49.85	18.04	64	26629	39709	79677986
Product use issue	49.55	18.04	6	26687	209816	79507879
Pulmonary function test decreased	48.93	18.04	31	26662	7606	79710089
Musculoskeletal stiffness	46.72	18.04	3	26690	175005	79542690
General physical health deterioration	46.60	18.04	199	26494	275039	79442656
Pain	46.06	18.04	105	26588	703697	79013998
Arthralgia	45.46	18.04	76	26617	571727	79145968
Treatment failure	45.29	18.04	3	26690	170483	79547212
White blood cell count decreased	44.99	18.04	152	26541	188136	79529559
Neutrophil count decreased	44.92	18.04	98	26595	93861	79623834
Arthropathy	44.56	18.04	4	26689	177107	79540588
Drug interaction	42.28	18.04	46	26647	415137	79302558
Condition aggravated	42.28	18.04	64	26629	501060	79216635
Hepatotoxicity	41.38	18.04	67	26626	51285	79666410
Polyneuropathy	40.36	18.04	45	26648	24106	79693589
Confusional state	39.85	18.04	29	26664	317968	79399727
Pneumonia bacterial	39.36	18.04	40	26653	19291	79698404
Swelling	39.02	18.04	12	26681	216699	79500996
Taste disorder	38.31	18.04	36	26657	15787	79701908
Pneumonitis	38.07	18.04	71	26622	60789	79656906
Pulmonary fibrosis	37.53	18.04	59	26634	44053	79673642
Metastases to meninges	37.39	18.04	20	26673	3581	79714114
Hypersensitivity	36.83	18.04	21	26672	262218	79455477
Product dose omission issue	34.51	18.04	20	26673	247517	79470178
Transaminases increased	34.42	18.04	62	26631	51681	79666014
Peripheral sensory neuropathy	34.17	18.04	31	26662	13002	79704693
Disease progression	34.08	18.04	137	26556	184225	79533470
Oxygen consumption increased	33.88	18.04	21	26672	4958	79712737
Overdose	33.52	18.04	10	26683	184196	79533499
Large intestine perforation	33.10	18.04	32	26661	14535	79703160
Asthma	31.55	18.04	4	26689	135091	79582604
Intestinal haemorrhage	31.31	18.04	22	26671	6404	79711291
Haemoglobin decreased	30.88	18.04	18	26675	222101	79495594
Gastrooesophageal reflux disease	29.28	18.04	89	26604	104157	79613538
Abdominal discomfort	29.25	18.04	163	26530	250564	79467131
Total lung capacity abnormal	29.02	18.04	8	26685	228	79717467
Rheumatoid arthritis	28.83	18.04	17	26676	208453	79509242
Wound	28.23	18.04	3	26690	116176	79601519
Febrile neutropenia	27.49	18.04	151	26542	230848	79486847
Hepatic enzyme increased	26.35	18.04	126	26567	182484	79535211
Bradycardia	25.32	18.04	7	26686	135550	79582145
Dehydration	24.84	18.04	155	26538	248032	79469663
Pericarditis	24.55	18.04	3	26690	104233	79613462
Diarrhoea haemorrhagic	24.45	18.04	26	26667	13208	79704487
Hypotension	23.91	18.04	72	26621	440245	79277450
Weight increased	23.77	18.04	35	26658	277351	79440344
Coating in mouth	23.34	18.04	7	26686	271	79717424
Performance status decreased	23.19	18.04	18	26675	6095	79711600
Pemphigus	23.13	18.04	3	26690	99579	79618116
Post procedural pneumonia	22.99	18.04	6	26687	138	79717557
Sinusitis	22.98	18.04	19	26674	195482	79522213
Hypoxia	22.59	18.04	81	26612	103162	79614533
KL-6 increased	22.33	18.04	6	26687	155	79717540
Depressed level of consciousness	22.23	18.04	3	26690	96649	79621046
Malignant neoplasm of pleura	22.04	18.04	6	26687	163	79717532
Diverticulitis	22.04	18.04	48	26645	45888	79671807
Product use in unapproved indication	22.03	18.04	31	26662	250328	79467367
Acute respiratory failure	21.81	18.04	56	26637	59485	79658210
Dysgeusia	21.17	18.04	54	26639	57123	79660572
Dermatitis acneiform	20.93	18.04	21	26672	9972	79707723
Agitation	20.91	18.04	4	26689	99711	79617984
Discomfort	20.80	18.04	8	26685	125609	79592086
Dairy intolerance	20.76	18.04	5	26688	82	79717613
Pneumothorax spontaneous	20.72	18.04	10	26683	1444	79716251
Aspartate aminotransferase increased	20.24	18.04	96	26597	138545	79579150
Neutropenic sepsis	20.04	18.04	34	26659	27030	79690665
Hypoglycaemia	19.44	18.04	5	26688	101589	79616106
Systemic scleroderma	19.41	18.04	9	26684	1188	79716507
Tumour pain	19.03	18.04	11	26682	2288	79715407
Obstruction gastric	18.85	18.04	10	26683	1760	79715935
Somnolence	18.72	18.04	32	26661	238949	79478746
Alanine aminotransferase increased	18.48	18.04	105	26588	162465	79555230
Anaphylactic reaction	18.34	18.04	3	26690	83740	79633955
Asthenia	18.30	18.04	256	26437	511433	79206262
Urticaria	18.29	18.04	21	26672	185180	79532515
Faeces discoloured	18.23	18.04	34	26659	29093	79688602

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L01EX09	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS PROTEIN KINASE INHIBITORS Other protein kinase inhibitors
FDA MoA	N0000175076	Protein Kinase Inhibitors
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D047428	Protein Kinase Inhibitors
FDA EPC	N0000175605	Kinase Inhibitor
CHEBI has role	CHEBI:35610	antineoplastic agents
CHEBI has role	CHEBI:38637	tyrosine kinase inhibitors
CHEBI has role	CHEBI:48422	angiogenesis antagonist
CHEBI has role	CHEBI:63457	FGFR inhibitors
CHEBI has role	CHEBI:65207	vascular endothelial growth factor receptor inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Interstitial fibrosis	indication	125565008
Systemic sclerosis associated interstitial lung disease	indication	233703007	DOID:3082
Non-small cell lung cancer	indication	254637007	DOID:3908
Idiopathic pulmonary fibrosis	indication	700250006	DOID:0050156

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.97	acidic
pKa2	7.77	Basic
pKa3	3.25	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
EQ 100MG BASE	OFEV	BOEHRINGER INGELHEIM	N205832	Oct. 15, 2014	RX	CAPSULE	ORAL	10154990	Jan. 8, 2026	USE OF NINTEDANIB FOR SLOWING THE RATE OF DECLINE IN PULMONARY FUNCTION IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD)
EQ 150MG BASE	OFEV	BOEHRINGER INGELHEIM	N205832	Oct. 15, 2014	RX	CAPSULE	ORAL	10154990	Jan. 8, 2026	USE OF NINTEDANIB FOR SLOWING THE RATE OF DECLINE IN PULMONARY FUNCTION IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD)

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
EQ 100MG BASE	OFEV	BOEHRINGER INGELHEIM	N205832	Oct. 15, 2014	RX	CAPSULE	ORAL	March 9, 2023	TREATMENT FOR CHRONIC FIBROSING INTERSTITIAL LUNG DISEASES WITH A PROGRESSIVE PHENOTYPE
EQ 150MG BASE	OFEV	BOEHRINGER INGELHEIM	N205832	Oct. 15, 2014	RX	CAPSULE	ORAL	March 9, 2023	TREATMENT FOR CHRONIC FIBROSING INTERSTITIAL LUNG DISEASES WITH A PROGRESSIVE PHENOTYPE
EQ 100MG BASE	OFEV	BOEHRINGER INGELHEIM	N205832	Oct. 15, 2014	RX	CAPSULE	ORAL	Sept. 6, 2026	INDICATED TO SLOW THE RATE OF DECLINE IN PULMONARY FUNCTION IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD)
EQ 150MG BASE	OFEV	BOEHRINGER INGELHEIM	N205832	Oct. 15, 2014	RX	CAPSULE	ORAL	Sept. 6, 2026	INDICATED TO SLOW THE RATE OF DECLINE IN PULMONARY FUNCTION IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD)

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Fibroblast growth factor receptor 3	Kinase	P22607	FGFR3_HUMAN	INHIBITOR	Kd	7.03	CHEMBL	CHEMBL
Platelet-derived growth factor receptor beta	Kinase	P09619	PGFRB_HUMAN	INHIBITOR	Kd	7.82	CHEMBL	CHEMBL
Fibroblast growth factor receptor 2	Kinase	P21802	FGFR2_HUMAN	INHIBITOR	Kd	6.46	CHEMBL	CHEMBL
Fibroblast growth factor receptor 4	Kinase	P22455	FGFR4_HUMAN	INHIBITOR	Kd	5.74	CHEMBL	CHEMBL
Vascular endothelial growth factor receptor 1	Kinase	P17948	VGFR1_HUMAN	INHIBITOR	IC50	6.98	SCIENTIFIC LITERATURE	SCIENTIFIC LITERATURE
Vascular endothelial growth factor receptor 2	Kinase	P35968	VGFR2_HUMAN	INHIBITOR	IC50	8.30	SCIENTIFIC LITERATURE	SCIENTIFIC LITERATURE
Vascular endothelial growth factor receptor 3	Kinase	P35916	VGFR3_HUMAN	INHIBITOR	IC50	8.30	SCIENTIFIC LITERATURE	SCIENTIFIC LITERATURE
Platelet-derived growth factor receptor alpha	Kinase	P16234	PGFRA_HUMAN	INHIBITOR	IC50	7.75	SCIENTIFIC LITERATURE	SCIENTIFIC LITERATURE
Fibroblast growth factor receptor 1	Kinase	P11362	FGFR1_HUMAN	INHIBITOR	IC50	7.42	SCIENTIFIC LITERATURE	SCIENTIFIC LITERATURE
Breakpoint cluster region protein	Kinase	P11274	BCR_HUMAN		Kd	6.52	CHEMBL
Proto-oncogene tyrosine-protein kinase Src	Kinase	P12931	SRC_HUMAN		Kd	6.24	CHEMBL
Tyrosine-protein kinase Lck	Kinase	P06239	LCK_HUMAN		Kd	8.21	CHEMBL
Tyrosine-protein kinase Yes	Kinase	P07947	YES_HUMAN		Kd	7.10	CHEMBL
Tyrosine-protein kinase Fyn	Kinase	P06241	FYN_HUMAN		Kd	6.20	CHEMBL
Ephrin type-A receptor 2	Kinase	P29317	EPHA2_HUMAN		Kd	5.54	CHEMBL
Receptor-type tyrosine-protein kinase FLT3	Kinase	P36888	FLT3_HUMAN		Kd	9.38	CHEMBL
Proto-oncogene tyrosine-protein kinase receptor Ret	Kinase	P07949	RET_HUMAN		Kd	8.02	CHEMBL
Macrophage colony-stimulating factor 1 receptor	Kinase	P07333	CSF1R_HUMAN		Kd	7.32	CHEMBL
Ribosomal protein S6 kinase alpha-3	Kinase	P51812	KS6A3_HUMAN		Kd	7.19	CHEMBL
Phosphorylase b kinase gamma catalytic chain, liver/testis isoform	Kinase	P15735	PHKG2_HUMAN		Kd	6.59	CHEMBL
Cyclin-dependent kinase 2	Kinase	P24941	CDK2_HUMAN		Kd	5.85	CHEMBL
Insulin-like growth factor 1 receptor	Kinase	P08069	IGF1R_HUMAN		Kd	7.21	CHEMBL
Myosin light chain kinase, smooth muscle	Kinase	Q15746	MYLK_HUMAN		Kd	6.54	CHEMBL
Insulin receptor	Kinase	P06213	INSR_HUMAN	AGONIST	Kd	7.62	CHEMBL
Death-associated protein kinase 3	Kinase	O43293	DAPK3_HUMAN		Kd	5.68	CHEMBL
Calcium/calmodulin-dependent protein kinase type 1	Kinase	Q14012	KCC1A_HUMAN		Kd	5.23	CHEMBL
Mitogen-activated protein kinase 8	Kinase	P45983	MK08_HUMAN		Kd	6.20	CHEMBL
Focal adhesion kinase 1	Kinase	Q05397	FAK1_HUMAN		Kd	6.68	CHEMBL
Tyrosine-protein kinase HCK	Kinase	P08631	HCK_HUMAN		Kd	5.28	CHEMBL
Tyrosine-protein kinase JAK1	Kinase	P23458	JAK1_HUMAN		Kd	8.32	CHEMBL
Mitogen-activated protein kinase 10	Kinase	P53779	MK10_HUMAN		Kd	6.57	CHEMBL
Death-associated protein kinase 2	Kinase	Q9UIK4	DAPK2_HUMAN		Kd	5.49	CHEMBL
High affinity nerve growth factor receptor	Kinase	P04629	NTRK1_HUMAN		Kd	8.35	CHEMBL
Tyrosine-protein kinase JAK2	Kinase	O60674	JAK2_HUMAN		Kd	7.85	CHEMBL
Myosin light chain kinase 2, skeletal/cardiac muscle	Kinase	Q9H1R3	MYLK2_HUMAN		Kd	5.40	CHEMBL
Angiopoietin-1 receptor	Kinase	Q02763	TIE2_HUMAN		Kd	5.85	CHEMBL
AP2-associated protein kinase 1	Kinase	Q2M2I8	AAK1_HUMAN		Kd	7.20	CHEMBL
Serine/threonine-protein kinase MARK2	Kinase	Q7KZI7	MARK2_HUMAN		Kd	5.85	CHEMBL
Hepatocyte growth factor receptor	Kinase	P08581	MET_HUMAN		Kd	6.70	CHEMBL
Tyrosine-protein kinase Lyn	Kinase	P07948	LYN_HUMAN		Kd	6.03	CHEMBL
Ribosomal protein S6 kinase alpha-2	Kinase	Q15349	KS6A2_HUMAN		Kd	7.24	CHEMBL
5'-AMP-activated protein kinase catalytic subunit alpha-1	Kinase	Q13131	AAPK1_HUMAN		Kd	7.06	CHEMBL
Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform	Kinase	Q16816	PHKG1_HUMAN		Kd	6.85	CHEMBL
Serine/threonine-protein kinase PLK4	Kinase	O00444	PLK4_HUMAN		Kd	7.28	CHEMBL
Aurora kinase C	Kinase	Q9UQB9	AURKC_HUMAN		Kd	6.72	CHEMBL
Serine/threonine-protein kinase 16	Kinase	O75716	STK16_HUMAN		Kd	7.74	CHEMBL
Dual specificity protein kinase TTK	Kinase	P33981	TTK_HUMAN		Kd	7.66	CHEMBL
Abelson tyrosine-protein kinase 2	Kinase	P42684	ABL2_HUMAN		Kd	5.70	CHEMBL
Serine/threonine-protein kinase N1	Kinase	Q16512	PKN1_HUMAN		Kd	6.13	CHEMBL
Protein kinase C theta type	Kinase	Q04759	KPCT_HUMAN		Kd	5.26	CHEMBL
Serine/threonine-protein kinase 17A	Kinase	Q9UEE5	ST17A_HUMAN		Kd	6.96	CHEMBL
Ephrin type-A receptor 6	Kinase	Q9UF33	EPHA6_HUMAN		Kd	6.03	CHEMBL
TRAF2 and NCK-interacting protein kinase	Kinase	Q9UKE5	TNIK_HUMAN		Kd	7.28	CHEMBL
Casein kinase I isoform epsilon	Kinase	P49674	KC1E_HUMAN		Kd	6.64	CHEMBL
Tyrosine-protein kinase Fgr	Kinase	P09769	FGR_HUMAN		Kd	6.52	CHEMBL
ALK tyrosine kinase receptor	Kinase	Q9UM73	ALK_HUMAN		Kd	7.51	CHEMBL
Ephrin type-A receptor 3	Kinase	P29320	EPHA3_HUMAN		Kd	5.07	CHEMBL
BMP-2-inducible protein kinase	Kinase	Q9NSY1	BMP2K_HUMAN		Kd	8.66	CHEMBL
Tyrosine-protein kinase FRK	Kinase	P42685	FRK_HUMAN		Kd	5.57	CHEMBL
Dual specificity protein kinase CLK1	Kinase	P49759	CLK1_HUMAN		Kd	8.06	CHEMBL
Dual specificity protein kinase CLK2	Kinase	P49760	CLK2_HUMAN		Kd	6.12	CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 5	Kinase	Q9Y4K4	M4K5_HUMAN		Kd	6.41	CHEMBL
Glycogen synthase kinase-3 beta	Kinase	P49841	GSK3B_HUMAN		Kd	7.08	CHEMBL
Ephrin type-B receptor 1	Kinase	P54762	EPHB1_HUMAN		Kd	6.26	CHEMBL
Calcium/calmodulin-dependent protein kinase type 1D	Kinase	Q8IU85	KCC1D_HUMAN		Kd	5.66	CHEMBL
Cyclin-dependent kinase 16	Kinase	Q00536	CDK16_HUMAN		Kd	7.68	CHEMBL
Serine/threonine-protein kinase 4	Kinase	Q13043	STK4_HUMAN		Kd	8.05	CHEMBL
Activated CDC42 kinase 1	Kinase	Q07912	ACK1_HUMAN		Kd	5.80	CHEMBL
Ribosomal protein S6 kinase alpha-5	Kinase	O75582	KS6A5_HUMAN		Kd	6.70	CHEMBL
STE20-like serine/threonine-protein kinase	Kinase	Q9H2G2	SLK_HUMAN		Kd	7.29	CHEMBL
Dual specificity protein kinase CLK4	Kinase	Q9HAZ1	CLK4_HUMAN		Kd	7.74	CHEMBL
Calcium/calmodulin-dependent protein kinase kinase 2	Kinase	Q96RR4	KKCC2_HUMAN		Kd	6.04	CHEMBL
MAP/microtubule affinity-regulating kinase 3	Kinase	P27448	MARK3_HUMAN		Kd	6.11	CHEMBL
Calcium/calmodulin-dependent protein kinase kinase 1	Kinase	Q8N5S9	KKCC1_HUMAN		Kd	6.20	CHEMBL
Calcium/calmodulin-dependent protein kinase type 1G	Kinase	Q96NX5	KCC1G_HUMAN		Kd	6.59	CHEMBL
Epithelial discoidin domain-containing receptor 1	Kinase	Q08345	DDR1_HUMAN		Kd	7.92	CHEMBL
Ephrin type-B receptor 4	Kinase	P54760	EPHB4_HUMAN		Kd	5.96	CHEMBL
Testis-specific serine/threonine-protein kinase 1	Kinase	Q9BXA7	TSSK1_HUMAN		Kd	5.21	CHEMBL
Activin receptor type-1B	Kinase	P36896	ACV1B_HUMAN		Kd	5.31	CHEMBL
Serine/threonine-protein kinase receptor R3	Kinase	P37023	ACVL1_HUMAN		Kd	5.38	CHEMBL
Activin receptor type-1	Kinase	Q04771	ACVR1_HUMAN		Kd	6.22	CHEMBL
3-phosphoinositide-dependent protein kinase 1	Kinase	O15530	PDPK1_HUMAN		Kd	5.55	CHEMBL
Dual specificity mitogen-activated protein kinase kinase 1	Kinase	Q02750	MP2K1_HUMAN		Kd	8	CHEMBL
Dual specificity mitogen-activated protein kinase kinase 2	Kinase	P36507	MP2K2_HUMAN		Kd	7.38	CHEMBL
Tyrosine-protein kinase ITK/TSK	Kinase	Q08881	ITK_HUMAN		Kd	6.68	CHEMBL
Tyrosine-protein kinase ZAP-70	Kinase	P43403	ZAP70_HUMAN		Kd	5.46	CHEMBL
Glycogen synthase kinase-3 alpha	Kinase	P49840	GSK3A_HUMAN		Kd	6.37	CHEMBL
Tyrosine-protein kinase BTK	Kinase	Q06187	BTK_HUMAN		Kd	6.51	CHEMBL
Tyrosine-protein kinase receptor UFO	Kinase	P30530	UFO_HUMAN		Kd	7.92	CHEMBL
BDNF/NT-3 growth factors receptor	Kinase	Q16620	NTRK2_HUMAN		Kd	7.72	CHEMBL
Tyrosine-protein kinase receptor TYRO3	Kinase	Q06418	TYRO3_HUMAN		Kd	5.31	CHEMBL
Cyclin-dependent kinase 7	Kinase	P50613	CDK7_HUMAN		Kd	6.52	CHEMBL
Serine/threonine-protein kinase D1	Kinase	Q15139	KPCD1_HUMAN		Kd	6	CHEMBL
Ribosomal protein S6 kinase beta-1	Kinase	P23443	KS6B1_HUMAN		Kd	6.72	CHEMBL
Serine/threonine-protein kinase N2	Kinase	Q16513	PKN2_HUMAN		Kd	5.85	CHEMBL
Serine/threonine-protein kinase DCLK3	Kinase	Q9C098	DCLK3_HUMAN		Kd	6.11	CHEMBL
Serine/threonine-protein kinase 3	Kinase	Q13188	STK3_HUMAN		Kd	7.42	CHEMBL
Ribosomal protein S6 kinase alpha-6	Kinase	Q9UK32	KS6A6_HUMAN		Kd	6.64	CHEMBL
NUAK family SNF1-like kinase 2	Kinase	Q9H093	NUAK2_HUMAN		Kd	7.68	CHEMBL
Non-receptor tyrosine-protein kinase TNK1	Kinase	Q13470	TNK1_HUMAN		Kd	6.68	CHEMBL
Non-receptor tyrosine-protein kinase TYK2	Kinase	P29597	TYK2_HUMAN		Kd	7.43	CHEMBL
Serine/threonine-protein kinase Chk1	Kinase	O14757	CHK1_HUMAN		Kd	6.54	CHEMBL
Serine/threonine-protein kinase PAK 3	Kinase	O75914	PAK3_HUMAN		Kd	6.68	CHEMBL
Cyclin-dependent kinase 17	Kinase	Q00537	CDK17_HUMAN		Kd	7.03	CHEMBL
Cyclin-dependent kinase 18	Kinase	Q07002	CDK18_HUMAN		Kd	6.29	CHEMBL
Cyclin-dependent kinase 14	Kinase	O94921	CDK14_HUMAN		Kd	6.33	CHEMBL
Phosphatidylinositol 4-phosphate 5-kinase type-1 alpha	Kinase	Q99755	PI51A_HUMAN		Kd	7.31	CHEMBL
Phosphatidylinositol 5-phosphate 4-kinase type-2 beta	Kinase	P78356	PI42B_HUMAN		Kd	7.77	CHEMBL
Myosin light chain kinase family member 4	Kinase	Q86YV6	MYLK4_HUMAN		Kd	6.36	CHEMBL
Wee1-like protein kinase	Kinase	P30291	WEE1_HUMAN		Kd	5.54	CHEMBL
Protein-tyrosine kinase 2-beta	Kinase	Q14289	FAK2_HUMAN		Kd	7.09	CHEMBL
Serine/threonine-protein kinase RIO1	Kinase	Q9BRS2	RIOK1_HUMAN		Kd	7.64	CHEMBL
Casein kinase I isoform delta	Kinase	P48730	KC1D_HUMAN		Kd	5.89	CHEMBL
Tyrosine-protein kinase receptor Tie-1	Kinase	P35590	TIE1_HUMAN		Kd	5.66	CHEMBL
NT-3 growth factor receptor	Kinase	Q16288	NTRK3_HUMAN		Kd	7.49	CHEMBL
Tyrosine-protein kinase TXK	Kinase	P42681	TXK_HUMAN		Kd	6.07	CHEMBL
Casein kinase II subunit alpha	Kinase	P68400	CSK21_HUMAN		Kd	5.12	CHEMBL
Casein kinase II subunit alpha'	Kinase	P19784	CSK22_HUMAN		Kd	6.05	CHEMBL
Dual specificity tyrosine-phosphorylation-regulated kinase 1B	Kinase	Q9Y463	DYR1B_HUMAN		Kd	5.80	CHEMBL
Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Kinase	Q14164	IKKE_HUMAN		Kd	6.77	CHEMBL
Serine/threonine-protein kinase STK11	Kinase	Q15831	STK11_HUMAN		Kd	7.74	CHEMBL
Dual specificity mitogen-activated protein kinase kinase 3	Kinase	P46734	MP2K3_HUMAN		Kd	5.68	CHEMBL
Maternal embryonic leucine zipper kinase	Kinase	Q14680	MELK_HUMAN		Kd	8.31	CHEMBL
Serine/threonine-protein kinase 26	Kinase	Q9P289	STK26_HUMAN		Kd	7.31	CHEMBL
Eukaryotic translation initiation factor 2-alpha kinase 4	Kinase	Q9P2K8	E2AK4_HUMAN		Kd	5.70	CHEMBL
Insulin receptor-related protein	Kinase	P14616	INSRR_HUMAN		Kd	7.68	CHEMBL
Interleukin-1 receptor-associated kinase 3	Kinase	Q9Y616	IRAK3_HUMAN		Kd	5.28	CHEMBL
Serine/threonine-protein kinase RIO3	Kinase	O14730	RIOK3_HUMAN		Kd	7.44	CHEMBL
Serine/threonine-protein kinase SIK2	Kinase	Q9H0K1	SIK2_HUMAN		Kd	6.55	CHEMBL
SRSF protein kinase 1	Kinase	Q96SB4	SRPK1_HUMAN		Kd	7.43	CHEMBL
SRSF protein kinase 2	Kinase	P78362	SRPK2_HUMAN		Kd	7.44	CHEMBL
Serine/threonine-protein kinase 33	Kinase	Q9BYT3	STK33_HUMAN		Kd	5.96	CHEMBL
5'-AMP-activated protein kinase catalytic subunit alpha-2	Kinase	P54646	AAPK2_HUMAN		Kd	7.08	CHEMBL
Discoidin domain-containing receptor 2	Kinase	Q16832	DDR2_HUMAN		Kd	7.38	CHEMBL
Serine/threonine-protein kinase LATS1	Kinase	O95835	LATS1_HUMAN		Kd	6.38	CHEMBL
Serine/threonine-protein kinase LATS2	Kinase	Q9NRM7	LATS2_HUMAN		Kd	6.42	CHEMBL
Leukocyte tyrosine kinase receptor	Kinase	P29376	LTK_HUMAN		Kd	6.82	CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 1	Kinase	Q92918	M4K1_HUMAN		Kd	7.46	CHEMBL
Serine/threonine-protein kinase PAK 7	Kinase	Q9P286	PAK5_HUMAN		Kd	5.89	CHEMBL
NUAK family SNF1-like kinase 1	Kinase	O60285	NUAK1_HUMAN		Kd	6.80	CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 3	Kinase	Q8IVH8	M4K3_HUMAN		Kd	6.54	CHEMBL
Aurora kinase B	Kinase	Q96GD4	AURKB_HUMAN		Kd	6.38	CHEMBL
Tyrosine-protein kinase Blk	Kinase	P51451	BLK_HUMAN		Kd	6.42	CHEMBL
Bone morphogenetic protein receptor type-2	Kinase	Q13873	BMPR2_HUMAN		Kd	7.25	CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 4	Kinase	O95819	M4K4_HUMAN		Kd	6.82	CHEMBL
Serine/threonine-protein kinase MARK1	Kinase	Q9P0L2	MARK1_HUMAN		Kd	5.85	CHEMBL
MAP/microtubule affinity-regulating kinase 4	Kinase	Q96L34	MARK4_HUMAN		Kd	5.70	CHEMBL
Dual specificity mitogen-activated protein kinase kinase 4	Kinase	P45985	MP2K4_HUMAN		Kd	5.43	CHEMBL
Tyrosine-protein kinase Mer	Kinase	Q12866	MERTK_HUMAN		Kd	8.07	CHEMBL
Calcium/calmodulin-dependent protein kinase type IV	Kinase	Q16566	KCC4_HUMAN		Kd	5.43	CHEMBL
Mitogen-activated protein kinase kinase kinase 9	Kinase	P80192	M3K9_HUMAN		Kd	6.66	CHEMBL
Mitogen-activated protein kinase kinase kinase 10	Kinase	Q02779	M3K10_HUMAN		Kd	5.64	CHEMBL
Mitogen-activated protein kinase kinase kinase 11	Kinase	Q16584	M3K11_HUMAN		Kd	6.15	CHEMBL
Serine/threonine-protein kinase 24	Kinase	Q9Y6E0	STK24_HUMAN		Kd	6.96	CHEMBL
Muscle, skeletal receptor tyrosine-protein kinase	Kinase	O15146	MUSK_HUMAN		Kd	6.23	CHEMBL
Serine/threonine-protein kinase DCLK1	Kinase	O15075	DCLK1_HUMAN		Kd	6.27	CHEMBL
Myosin-IIIb	Kinase	Q8WXR4	MYO3B_HUMAN		Kd	5.57	CHEMBL
Serine/threonine-protein kinase PAK 2	Kinase	Q13177	PAK2_HUMAN		Kd	5.48	CHEMBL
Serine/threonine-protein kinase PAK 4	Kinase	O96013	PAK4_HUMAN		Kd	5.52	CHEMBL
Cyclin-dependent kinase 3	Kinase	Q00526	CDK3_HUMAN		Kd	6.84	CHEMBL
Serine/threonine-protein kinase SIK1	Kinase	P57059	SIK1_HUMAN		Kd	6.17	CHEMBL
TGF-beta receptor type-1	Kinase	P36897	TGFR1_HUMAN		Kd	5.38	CHEMBL
Ephrin type-A receptor 1	Kinase	P21709	EPHA1_HUMAN		Kd	5.92	CHEMBL
Mitogen-activated protein kinase 7	Kinase	Q13164	MK07_HUMAN		Kd	5.60	CHEMBL
Serine/threonine-protein kinase D2	Kinase	Q9BZL6	KPCD2_HUMAN		Kd	6.14	CHEMBL
Serine/threonine-protein kinase D3	Kinase	O94806	KPCD3_HUMAN		Kd	6.19	CHEMBL
Receptor-interacting serine/threonine-protein kinase 1	Kinase	Q13546	RIPK1_HUMAN		Kd	6.62	CHEMBL
Tyrosine-protein kinase Fes/Fps	Kinase	P07332	FES_HUMAN		Kd	5.92	CHEMBL
Proto-oncogene tyrosine-protein kinase ROS	Kinase	P08922	ROS1_HUMAN		Kd	5.43	CHEMBL
Ribosomal protein S6 kinase alpha-1	Kinase	Q15418	KS6A1_HUMAN		Kd	6.74	CHEMBL
Ribosomal protein S6 kinase alpha-4	Kinase	O75676	KS6A4_HUMAN		Kd	6.21	CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 2	Kinase	Q12851	M4K2_HUMAN		Kd	6.54	CHEMBL
Misshapen-like kinase 1	Kinase	Q8N4C8	MINK1_HUMAN		Kd	7.09	CHEMBL
Serine/threonine-protein kinase TBK1	Kinase	Q9UHD2	TBK1_HUMAN		Kd	6.82	CHEMBL
Interleukin-1 receptor-associated kinase 4	Kinase	Q9NWZ3	IRAK4_HUMAN		Kd	6.09	CHEMBL
Cyclin-dependent kinase 4	Kinase	P11802	CDK4_HUMAN		Kd	6.80	CHEMBL
Cyclin-dependent kinase-like 2	Kinase	Q92772	CDKL2_HUMAN		Kd	5.89	CHEMBL
Ephrin type-B receptor 6	Kinase	O15197	EPHB6_HUMAN		Kd	6.85	CHEMBL
Serine/threonine-protein kinase/endoribonuclease IRE1	Kinase	O75460	ERN1_HUMAN		Kd	5.70	CHEMBL
Rhodopsin kinase	Kinase	Q15835	RK_HUMAN		Kd	6	CHEMBL
G protein-coupled receptor kinase 4	Kinase	P32298	GRK4_HUMAN		Kd	7.77	CHEMBL
G protein-coupled receptor kinase 7	Kinase	Q8WTQ7	GRK7_HUMAN		Kd	5.92	CHEMBL
Homeodomain-interacting protein kinase 2	Kinase	Q9H2X6	HIPK2_HUMAN		Kd	6.10	CHEMBL
Homeodomain-interacting protein kinase 3	Kinase	Q9H422	HIPK3_HUMAN		Kd	6.07	CHEMBL
Homeodomain-interacting protein kinase 4	Kinase	Q8NE63	HIPK4_HUMAN		Kd	5.92	CHEMBL
Serine/threonine-protein kinase ICK	Kinase	Q9UPZ9	ICK_HUMAN		Kd	5.77	CHEMBL
Inhibitor of nuclear factor kappa-B kinase subunit alpha	Kinase	O15111	IKKA_HUMAN		Kd	5.35	CHEMBL
Interleukin-1 receptor-associated kinase 1	Kinase	P51617	IRAK1_HUMAN		Kd	6.92	CHEMBL
Mitogen-activated protein kinase kinase kinase 13	Kinase	O43283	M3K13_HUMAN		Kd	6.85	CHEMBL
Mitogen-activated protein kinase kinase kinase 2	Kinase	Q9Y2U5	M3K2_HUMAN		Kd	8.03	CHEMBL
Mitogen-activated protein kinase kinase kinase 3	Kinase	Q99759	M3K3_HUMAN		Kd	7.47	CHEMBL
Microtubule-associated serine/threonine-protein kinase 1	Kinase	Q9Y2H9	MAST1_HUMAN		Kd	5.34	CHEMBL
Calcium/calmodulin-dependent protein kinase type II subunit alpha	Kinase	Q9UQM7	KCC2A_HUMAN		Kd	5.44	CHEMBL
SRSF protein kinase 3	Kinase	Q9UPE1	SRPK3_HUMAN		Kd	7.92	CHEMBL
STE20/SPS1-related proline-alanine-rich protein kinase	Kinase	Q9UEW8	STK39_HUMAN		Kd	6.28	CHEMBL
Mitogen-activated protein kinase kinase kinase 7	Kinase	O43318	M3K7_HUMAN		Kd	8.39	CHEMBL
Serine/threonine-protein kinase ULK1	Kinase	O75385	ULK1_HUMAN		Kd	6.47	CHEMBL
Serine/threonine-protein kinase ULK2	Kinase	Q8IYT8	ULK2_HUMAN		Kd	6.42	CHEMBL
Serine/threonine-protein kinase ULK3	Kinase	Q6PHR2	ULK3_HUMAN		Kd	7.22	CHEMBL
Mitogen-activated protein kinase kinase kinase 19	Kinase	Q56UN5	M3K19_HUMAN		Kd	8.28	CHEMBL
Homeodomain-interacting protein kinase 1	Kinase	Q86Z02	HIPK1_HUMAN		Kd	5.89	CHEMBL
Mitogen-activated protein kinase kinase kinase 15	Kinase	Q6ZN16	M3K15_HUMAN		Kd	5.85	CHEMBL
Receptor-interacting serine/threonine-protein kinase 4	Kinase	P57078	RIPK4_HUMAN		Kd	6.36	CHEMBL
Uncharacterized serine/threonine-protein kinase SBK3	Kinase	P0C264	SBK3_HUMAN		Kd	5.70	CHEMBL
Serine/threonine-protein kinase 35	Kinase	Q8TDR2	STK35_HUMAN		Kd	6.09	CHEMBL
Serine/threonine-protein kinase SBK1	Kinase	Q52WX2	SBK1_HUMAN		Kd	6.96	CHEMBL
Serine/threonine-protein kinase PRP4 homolog	Kinase	Q13523	PRP4B_HUMAN		Kd	8.08	CHEMBL
Mitogen-activated protein kinase kinase kinase 12	Kinase	Q12852	M3K12_HUMAN		Kd	6.85	CHEMBL
Serine/threonine-protein kinase Sgk3	Kinase	Q96BR1	SGK3_HUMAN		Kd	6	CHEMBL
Dual specificity mitogen-activated protein kinase kinase 5	Kinase	Q13163	MP2K5_HUMAN		Kd	8.74	CHEMBL
Myosin light chain kinase 3	Kinase	Q32MK0	MYLK3_HUMAN		Kd	6.96	CHEMBL
Leucine-rich repeat serine/threonine-protein kinase 2	Kinase	Q5S007	LRRK2_HUMAN		Kd	7.43	CHEMBL
cGMP-dependent protein kinase 1	Kinase	Q13976	KGP1_HUMAN		Kd	7.85	CHEMBL
Serine/threonine-protein kinase OSR1	Kinase	O95747	OXSR1_HUMAN		Kd	5.89	CHEMBL
Serine/threonine-protein kinase 17B	Kinase	O94768	ST17B_HUMAN		Kd	6.17	CHEMBL
Serine/threonine-protein kinase 10	Kinase	O94804	STK10_HUMAN		Kd	7.06	CHEMBL
Tyrosine-protein kinase JAK3	Kinase	P52333	JAK3_HUMAN		Kd	8.09	CHEMBL
Potassium voltage-gated channel subfamily H member 2	Ion channel	Q12809	KCNH2_HUMAN		IC50	8.59	CHEMBL
Multidrug resistance protein 1	Transporter	P08183	MDR1_HUMAN		EC50	6.56	CHEMBL
Tyrosine-protein kinase Fer	Kinase	P16591	FER_HUMAN		Kd	7.14	CHEMBL
Tyrosine-protein kinase ABL1	Kinase	P00519	ABL1_HUMAN		Kd	8	CHEMBL
Mast/stem cell growth factor receptor Kit	Kinase	P10721	KIT_HUMAN		Kd	8.57	CHEMBL
Calcium-dependent protein kinase 1	Kinase		CDPK1_PLAF7		Kd	5.92	CHEMBL
Vascular endothelial growth factor receptor 2	Kinase		VGFR2_MOUSE		IC50	7.89	CHEMBL
Serine/threonine-protein kinase PknB	Kinase		PKNB_MYCTU		Kd	8.44	CHEMBL

External reference:

ID	Source
G6HRD2P839	UNII
D10396	KEGG_DRUG
4033814	VUID
N0000191096	NUI
656247-18-6	SECONDARY_CAS_RN
4033814	VANDF
C2930789	UMLSCUI
CHEBI:85164	CHEBI
CHEMBL502835	ChEMBL_ID
135423438	PUBCHEM_CID
DB09079	DRUGBANK_ID
CHEMBL3039504	ChEMBL_ID
9229	INN_ID
C530716	MESH_SUPPLEMENTAL_RECORD_UI
5936	IUPHAR_LIGAND_ID
1592736	RXNORM
229920	MMSL
30617	MMSL
d08301	MMSL
015720	NDDF
015723	NDDF
712494002	SNOMEDCT_US
715613009	SNOMEDCT_US
863993005	SNOMEDCT_US
XIN	PDB_CHEM_ID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Ofev	HUMAN PRESCRIPTION DRUG LABEL	1	0597-0143	CAPSULE	100 mg	ORAL	NDA	31 sections
Ofev	HUMAN PRESCRIPTION DRUG LABEL	1	0597-0143	CAPSULE	100 mg	ORAL	NDA	31 sections
Ofev	HUMAN PRESCRIPTION DRUG LABEL	1	0597-0145	CAPSULE	150 mg	ORAL	NDA	31 sections
Ofev	HUMAN PRESCRIPTION DRUG LABEL	1	0597-0145	CAPSULE	150 mg	ORAL	NDA	31 sections